{"entity":{"id":"paper-nct05077449-nat-commun-2025","kind":"paper","name":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","aka":[],"tldr":"Published report from the trial registered as NCT05077449, in Nature Communications (2025), chosen as the most cited paper whose own text cites the registry id.","summary":"The BRIGHT-2 study (NCT05077449) is a randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of bireociclib plus fulvestrant (BF) vs. placebo plus fulvestrant (F) in Chinese female patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) who had progressed on or after prior endocrine therapy (ET). Interim results were analyzed after 70% of progression-free survival (PFS) events across 64 centers in China between December 8, 2021, and March 28, 2023. Patients were randomized (2:1) to receive BF or F, with stratification based on visceral involvement (yes/no) and resistance to prior primary or secondary ET. As the primary outcome, PFS was significantly prolonged in the BF group (n = 204) (12.94 months; 95% CI: 11.07-not reached) compared to 7.29 months (95% CI: 5.45-11.04) in the F group (n = 101) (hazard ratio, 0.56; 95% CI: 0.39-0.80; p = 0.001). The objective response rate in the BF group was 39.7% in the intention-to-treat population. Grade ≥3 adverse events were more frequent in the BF group (64.7%) than in the F group (18.8%), with neutropenia, leukopenia, and anemia being the most common. These findings suggest that BF is a promising therapeutic option for patients with HR+/HER2- ABC following ET failure.\n\nIndexed on Europe PMC as PubMed record 40204778 (DOI 10.1038/s41467-025-58647-z). Its abstract cites the registry id NCT05077449, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Nat Commun 2025","url":"https://doi.org/10.1038/s41467-025-58647-z"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40204778/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/40204778"},{"label":"ClinicalTrials.gov NCT05077449","url":"https://clinicaltrials.gov/study/NCT05077449"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05077449"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-communications"],"dependsOn":[],"notes":[],"journal":"Nature Communications","year":2025,"doi":"10.1038/s41467-025-58647-z","pmid":"40204778","authors":"Wang J, Zhang Q, Li H, et al.","paperType":"rct","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT05077449 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-nct05077449-nat-commun-2025/","neighbours":{"trial":[{"id":"nct05077449","kind":"trial","name":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","route":"/trials/nct05077449/"}],"journal":[{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/"}]}}